Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the...
Harbour BioMed
Harbour BioMed’s Batoclimab for Generalized Myasthenia Gravis Accepted for NMPA Review
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...
Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...
Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...
Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta
Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Nona Biosciences Partners with Mythic Therapeutics for Next-Gen ADCs
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership...
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study
China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...
TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody
China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...
Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics
Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...